©2022 Stanford Medicine
Prospective Observational Epidemiologic Study of Maraviroc's Safety
Not Recruiting
Trial ID: NCT00665561
Purpose
The study will assess if use of maraviroc along with an optimized background regimen of
antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen
of antiretroviral drugs.
Official Title
AN INTERNATIONAL, MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS
Stanford Investigator(s)
Philip Grant
Asst Prof-Univ Med Line, Medicine - Infectious Diseases
Eligibility
Inclusion Criteria:
- Treatment experienced, HIV-1 infected patients
- 18 years or older
- Receive an approved assay for determination of HIV-1 tropism
Exclusion Criteria:
- Pregnant or lactating
- Using CCR5 inhibitor other than maraviroc
Intervention(s):
drug: Maraviroc along with an optimized background antiretroviral drug regimen
drug: Optimized background antiretroviral drug regimen without maraviroc
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Debbie Slamowitz
(650) 723-2808